<table id="Table4" width="85%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 4: Active Metabolite Pharmacokinetics and Antiplatelet Responses by CYP2C19 Metabolizer Status</caption>
<col align="left" valign="top" width="25%"></col>
<col align="left" valign="top" width="15%"></col>
<col align="center" valign="top" width="15%"></col>
<col align="center" valign="top" width="15%"></col>
<col align="center" valign="top" width="15%"></col>
<col align="center" valign="top" width="15%"></col>
<thead>
<tr>
<th stylecode="Lrule"></th>
<th>Dose</th>
<th>Ultrarapid <br/>(n=10)</th>
<th>Extensive <br/>(n=10)</th>
<th>Intermediate <br/>(n=10)</th>
<th stylecode="Rrule">Poor <br/>(n=10)</th>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="6">Values are mean (SD)</td>
</tr>
</tfoot>
<tbody>
<tr>
<td stylecode="Lrule">Cmax (ng/mL)</td>
<td>300 mg (24 h)</td>
<td>24 (10)</td>
<td>32 (21)</td>
<td>23 (11)</td>
<td stylecode="Rrule">11 (4)</td>
</tr>
<tr>
<td stylecode="Lrule"></td>
<td>600 mg (24 h)</td>
<td>36 (13)</td>
<td>44 (27)</td>
<td>39 (23)</td>
<td stylecode="Rrule">17 (6)</td>
</tr>
<tr>
<td stylecode="Lrule"></td>
<td>75 mg (Day 5)</td>
<td>12 (6)</td>
<td>13 (7)</td>
<td>12 (5)</td>
<td stylecode="Rrule">4 (1)</td>
</tr>
<tr>
<td stylecode="Lrule"></td>
<td>150 mg (Day 5)</td>
<td>16 (9)</td>
<td>19 (5)</td>
<td>18 (7)</td>
<td stylecode="Rrule">7 (2)</td>
</tr>
<tr>
<td stylecode="Lrule">IPA (%)<footnote>Inhibition of platelet aggregation with 5mcM ADP; larger value indicates greater platelet inhibition</footnote>
</td>
<td>300 mg (24 h)</td>
<td>40 (21)</td>
<td>39 (28)</td>
<td>37 (21)</td>
<td stylecode="Rrule">24 (26)</td>
</tr>
<tr>
<td stylecode="Lrule"></td>
<td>600 mg (24 h)</td>
<td>51 (28)</td>
<td>49 (23)</td>
<td>56 (22)</td>
<td stylecode="Rrule">32 (25)</td>
</tr>
<tr>
<td stylecode="Lrule"></td>
<td>75 mg (Day 5)</td>
<td>56 (13)</td>
<td>58 (19)</td>
<td>60 (18)</td>
<td stylecode="Rrule">37 (23)</td>
</tr>
<tr>
<td stylecode="Lrule"></td>
<td>150 mg (Day 5)</td>
<td>68 (18)</td>
<td>73 (9)</td>
<td>74 (14)</td>
<td stylecode="Rrule">61 (14)</td>
</tr>
<tr>
<td stylecode="Lrule">VASP-PRI (%) <footnote>Vasodilator-stimulated phosphoprotein â€“ platelet reactivity index; smaller value indicates greater platelet inhibition</footnote>
</td>
<td>300 mg (24 h)</td>
<td>73 (12)</td>
<td>68 (16)</td>
<td>78 (12)</td>
<td stylecode="Rrule">91 (12)</td>
</tr>
<tr>
<td stylecode="Lrule"></td>
<td>600 mg (24 h)</td>
<td>51 (20)</td>
<td>48 (20)</td>
<td>56 (26)</td>
<td stylecode="Rrule">85 (14)</td>
</tr>
<tr>
<td stylecode="Lrule"></td>
<td>75 mg (Day 5)</td>
<td>40 (9)</td>
<td>39 (14)</td>
<td>50 (16)</td>
<td stylecode="Rrule">83 (13)</td>
</tr>
<tr>
<td stylecode="Lrule"></td>
<td>150 mg (Day 5)</td>
<td>20 (10)</td>
<td>24 (10)</td>
<td>29 (11)</td>
<td stylecode="Rrule">61 (18)</td>
</tr>
</tbody>
</table>